Anja Gesierich
Overview
Explore the profile of Anja Gesierich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Forschner A, Kahler K, Gschnell M, Langan E, Weishaupt C, Meiss F, et al.
Front Immunol
. 2025 Mar;
16:1509886.
PMID: 40066437
Background: Although systemic therapies have improved considerably over the last decade, up to 50% of patients with metastatic melanoma still die due to disease progression. Oncological treatment at the end-of-life...
2.
Reitmajer M, Livingstone E, Thoms K, Heppt M, Meiss F, Gesierich A, et al.
J Dtsch Dermatol Ges
. 2025 Jan;
23(3):321-327.
PMID: 39748658
Background: Up to now, the optimal duration of immune checkpoint inhibitors (ICI) has not been evaluated in prospective studies. However, current clinical practice requires decisions to be made regarding the...
3.
Glutsch V, Schummer P, Goebeler M, Gesierich A, Schilling B
Front Immunol
. 2024 Dec;
15:1495004.
PMID: 39703511
Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous malignancy. Immune checkpoint inhibition (ICI) with PD-(L)1 blockade has significantly improved treatment outcomes in metastatic disease. In patients...
4.
Wagenhauser I, Knies K, Pscheidl T, Eisenmann M, Flemming S, Petri N, et al.
EBioMedicine
. 2024 Oct;
109:105394.
PMID: 39388783
Background: SARS-CoV-2 antigen rapid detection tests (RDTs) emerged as point-of-care diagnostics alongside reverse transcription polymerase chain reaction (RT-qPCR) as reference. Methods: In a prospective performance assessment from 12 November 2020...
5.
Zager J, Orloff M, Ferrucci P, Choi J, Eschelman D, Glazer E, et al.
Ann Surg Oncol
. 2024 Jul;
31(12):8262-8263.
PMID: 39026142
No abstract available.
6.
Koch E, Petzold A, Dippel E, Erdmann M, Gesierich A, Gutzmer R, et al.
Front Immunol
. 2024 Jun;
15:1395225.
PMID: 38915414
Introduction: Despite recent advancements in the treatment of metastatic uveal melanoma (UM), the availability of further treatment options remains limited and the prognosis continues to be poor in many cases....
7.
Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils
Wendlinger S, Wohlfarth J, Siedel C, Kreft S, Kilian T, Junker S, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730718
Elevated levels of peripheral blood and tumor tissue neutrophils are associated with poorer clinical response and therapy resistance in melanoma. The underlying mechanism and the role of neutrophils in targeted...
8.
Zager J, Orloff M, Ferrucci P, Choi J, Eschelman D, Glazer E, et al.
Ann Surg Oncol
. 2024 May;
31(8):5340-5351.
PMID: 38704501
Background: Uveal melanoma (UM) has a poor prognosis once liver metastases occur. The melphalan/Hepatic Delivery System (melphalan/HDS) is a drug/device combination used for liver-directed treatment of metastatic UM (mUM) patients....
9.
Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, et al.
Eur J Cancer
. 2024 Apr;
203:114028.
PMID: 38652976
Background: Immune checkpoint inhibitors (ICI) induce adverse events (irAEs) that do not respond to steroids, i.e. steroid-refractory (sr) irAEs, and irAEs in which steroids cannot be tapered, i.e. steroid-dependent (sd)...
10.
Knies K, Wagenhauser I, Hofmann D, Rauschenberger V, Eisenmann M, Reusch J, et al.
Dtsch Arztebl Int
. 2023 Dec;
120(45):763-764.
PMID: 38051563
No abstract available.